Mink Therapeutics Inc Cash Flow Conversion Efficiency
Mink Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Mink Therapeutics Inc (INKT) has a cash flow conversion efficiency ratio of 0.148x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.08 Million) by net assets ($-14.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mink Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Mink Therapeutics Inc from 2019 to 2025. This chart illustrates how Mink Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INKT stock price for real-time trading data and today's change.
Mink Therapeutics Inc Cash Flow Conversion Ratio Explained
Mink Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mink Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mink Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Mink Therapeutics Inc (INKT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Broad Capital Acquisition Corp
NASDAQ:BRAC
|
0.008x |
|
Ahoku Electronic Co
TW:3002
|
-0.016x |
|
Saehwa IMC Co Ltd
KO:145210
|
0.026x |
|
Hong Ho Precision Textile Co Ltd
TW:1446
|
0.002x |
|
Osteonic Co. Ltd
KQ:226400
|
0.017x |
|
Farmsco
KO:036580
|
0.031x |
|
XTPL SA
WAR:XTP
|
-0.711x |
|
ADOLFO DOMINGUEZ
MC:ADZ
|
0.253x |
Annual Cash Flow Conversion Efficiency for Mink Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mink Therapeutics Inc from 2019 to 2025. Review INKT financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-14.23 Million | $-5.93 Million | 0.416x | -14.64% |
| 2024-12-31 | $-19.59 Million | $-9.56 Million | 0.488x | -44.12% |
| 2023-12-31 | $-18.06 Million | $-15.76 Million | 0.873x | -98.14% |
| 2022-12-31 | $-401.30K | $-18.87 Million | 47.014x | +8814.55% |
| 2021-12-31 | $23.78 Million | $-12.83 Million | -0.539x | -448.59% |
| 2020-12-31 | $-53.87 Million | $-8.34 Million | 0.155x | -62.37% |
| 2019-12-31 | $-36.33 Million | $-14.94 Million | 0.411x | -- |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more